Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

Panelists discuss how:
Ttherapeutic sequencing in advanced HER2-positive disease has become increasingly complex. The experts review data supporting novel ADCsantibody-drug conjugates, TKIstyrosine kinase inhibitors, and combination regimens used beyond first-line therapy. They emphasize strategic sequencing to overcome resistance, preserve performance status, and extend survival. The conversation also covers real-world barriers such as treatment accessibility, toxicity management, and quality-of-life considerations when transitioning between lines.